A new framework for paediatric cancer protocol translation

A New Framework for Translating Paediatric Cancer Research into Clinical Protocols offers a practical route from promising findings to dependable care. Rather than moving directly from a trial result to a hospital guideline, it joins evidence appraisal, protocol design, governance, pilot testing and measurement. The result is a traceable pathway that shows who made each decision, why it was made and how safety will be monitored.

For Brisbane and regional Queensland teams, the value is strongest when children, families, carers, clinicians and researchers shape the same pathway. A shared method can reduce variation between tertiary centres, support smaller services and keep protocols responsive to new evidence as it emerges.

Why translation needs its own framework

Paediatric cancer protocols combine molecular or risk classification with intensive medicines, surgery, radiotherapy and supportive care. Evidence about one component may not transfer neatly to a child’s age, developmental stage, comorbidity or access to specialist services. A protocol therefore needs a translation layer that tests whether an intervention is safe, feasible and clinically meaningful in local practice.

A structured layer also creates accountability. Clinicians can see which recommendations are supported by high-quality evidence, which are consensus-based because evidence is sparse, and which require prospective audit. Version control, ownership and a scheduled review prevent a document developed for one ward or study from becoming an unexamined standard across a network.

Co-designing around Australian families

Children and families should be involved before recommendations are settled, not consulted after a technical document is complete. Co-design groups can test whether an outcome reflects what matters to a child and family, whether written information is readable and whether the proposed pathway works for people who speak languages other than English. Bereaved families and patient advocates can also identify burdens that trial data may not capture.

Queensland’s geography adds practical questions. Some children travel from the Gold Coast, Townsville or remote communities to Brisbane for diagnosis and treatment, often balancing hospital appointments with school and work routines for the wider family. Telehealth can support review and follow-up, but a protocol should allow a local paediatrician or nurse to escalate concerns without assuming families have reliable internet or private space for a consultation. This is where Brisbane Diamantina Health Partners can act as the connective tissue between research institutes, universities and health services, helping local teams share consumer input and implementation experience.

Building the evidence-to-protocol pathway

The first step is a prioritisation checkpoint. A translation group should define the clinical problem, affected population, evidence base and expected benefit, then assign an evidence lead, clinical owner and implementation lead. Questions that change diagnosis, prognosis or treatment intensity require early review by appropriate tumour-specific and paediatric specialists; supportive-care proposals may follow a different risk pathway.

The protocol draft should be operational rather than a summary of a paper. It needs eligibility criteria, treatment sequence, dosing and adjustment rules, toxicity thresholds, monitoring, imaging or laboratory review, supportive care, stop rules and documentation. Named clinicians must know who makes urgent decisions at night and when treatment should move to intensive care. Every recommendation should carry its source and an evidence grade, with local consensus clearly labelled.

Australian implementation should then be specified. Australia’s paediatric oncology market is concentrated in metropolitan tertiary services, so national trial evidence may enter through a small number of referral hubs before reaching regional teams. The framework should map pharmacy and pathology capacity, tele-oncology access, credentialing, transfer arrangements and cost impacts. Eligible outpatient medicines may draw on the Pharmaceutical Benefits Scheme, while inpatient supply and trial medicines depend on hospital formularies, TGA pathways and sponsor agreements. Those local supply chains belong in the protocol from the start.

Governance that protects children and trust

Research involving children must follow the NHMRC National Statement, relevant state approvals and site-specific ethics requirements. A protocol intended for routine care needs clinical governance approval, while prospective evaluation may also require research ethics review, participant consent or waiver, and registration in the ANZCTR. Oversight should cover consent, confidentiality, data security, conflicts of interest and reporting of adverse events; there is no sensible reason to blur research and quality-improvement responsibilities.

The privacy assessment should address the Privacy Act 1988 and the Australian Privacy Principles, along with Queensland Health information-governance requirements for participating services. Data flows, storage, access and retention should be documented before data collection begins. Aboriginal and Torres Strait Islander children and communities require appropriate governance and culturally safe engagement, including local leadership where data concern their communities. Independent safety monitoring, clear escalation pathways and routine audits make trust visible to families and accountable to the clinicians responsible for care.

Piloting, measuring and refining change

A protocol should enter practice through a staged pilot with predefined acceptance criteria. This might mean retrospective case review first, simulation or multidisciplinary case conference second, and a limited prospective cohort third. Outcomes should cover clinical safety and effectiveness alongside access, waiting time, unplanned admission, treatment disruption and family burden. Collecting implementation measures from the outset reveals whether evidence is being translated into better care.

Knowledge exchange should continue after launch. Methods and partnership models used by the international HARP FP7 programme offer a useful cross-border reference for structured collaboration and knowledge exchange. Locally, tumour groups can review exceptions monthly and the full protocol every six or twelve months, or sooner when safety evidence changes. Each update should record the decision, evidence, responsible group and next review date. A transparent audit trail supports incident review and lets smaller Queensland services contribute observations without waiting for a central committee to discover them.

Turning collaboration into clinical action

The framework becomes useful when institutions assign responsibility rather than adding another document to a shared drive. Each partner should nominate a clinical owner, a research or evidence lead, a consumer and community representative, and an implementation coordinator. A small cross-organisational team can select one high-priority pathway, map the local workflow and agree the measures that will show whether uptake improves outcomes.

Commit now: nominate an institutional champion, convene a translation working group, pilot one protocol and publish the tools and evaluation methods through existing education and publication channels. If every participating organisation makes one commitment and reports against a common set of measures, research can move into daily practice with less friction, greater consistency and a clearer record of impact.